| Metric | Details |
|---|---|
| Entity / Legal Name | BioLife Plasma Services L.P. |
| Parent Company | Takeda Pharmaceutical Company Limited |
| S&P / Moody’s Rating (Takeda) | BBB‑ / Baa3 |
| Outlook | Stable (both agencies) |
| Investment Grade Status | Investment Grade — Lower-Medium Grade |
| Sector | Plasma Collection / Biopharmaceuticals |
| US Center Count | ~180+ |
| Cap Rate Range | 5.75–6.75% |
| Typical Lease Term | 10–20 years (NNN) |
| Guarantee Type | BioLife Plasma Services (Takeda subsidiary) |
| Parent Stock Ticker | TAK (NYSE / TSE) |
| Parent Annual Revenue | ~$31B USD (Takeda FY2024) |
| Typical Building Size | 8,000–15,000 SF |
| Typical Price Range | $3,000,000–$7,000,000 |
BioLife Plasma Services Business Overview & NNN Investment Profile
BioLife Plasma Services is one of the largest plasma collection networks in the United States, operating approximately 180+ plasma donation centers across major US markets. BioLife is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited — a Japan-based global biopharmaceutical company with approximately $31 billion in annual revenue — that uses the collected plasma as raw material for its immunoglobulin, albumin, and clotting factor therapies. The NNN lease guarantee on every BioLife center flows from this Takeda parent credit, making BioLife one of the few plasma collection operators with a direct investment-grade corporate guarantee.
Why Plasma Centers Are Compelling NNN Investments
Plasma donation centers occupy a unique position in the healthcare NNN landscape. Unlike medical offices dependent on insurance reimbursement rates or urgent care centers sensitive to patient volume fluctuations, plasma centers operate on a manufacturing input model: they collect source plasma from donors, which Takeda processes into life-saving medicines. Demand for plasma-derived therapies — particularly immunoglobulins used to treat immune deficiencies, neurological conditions, and rare diseases — is secular and growing driven by an aging population and expanding indications.
The plasma collection model creates exceptionally sticky locations. Centers build loyal donor pools over years — donors often visit twice weekly for the compensation — creating a community-embedded operation that makes relocation costly and disruptive. BioLife’s typical 10 to 20 year NNN leases reflect this location commitment.
BioLife NNN Lease Structure
BioLife NNN leases carry 10 to 20 year initial terms with annual rent escalations of 2% to 3%. The 8,000 to 15,000 SF format occupies strip center and freestanding suburban locations with strong visibility, accessibility, and parking — critical for donor convenience. The specialized plasma collection buildout (donor beds, centrifuges, sterile processing areas) represents significant tenant improvement investment that strongly supports long-term lease commitment. Accessible acquisition prices of $3,000,000 to $7,000,000 make BioLife centers viable for individual investors and 1031 exchange buyers seeking investment-grade healthcare NNN.
BioLife NNN Cap Rate & Pricing
BioLife NNN properties trade at cap rates between 5.75% and 6.75% as of Q1 2026. The BBB‑/Baa3 Takeda parent credit positions BioLife at the investment-grade healthcare NNN tier — tighter than unrated plasma operators (CSL Plasma, Octapharma) and comparable to other pharmaceutical/healthcare investment-grade tenants. High-traffic suburban locations with long remaining lease terms and demonstrated donor retention command the tightest spreads.
Comparable NNN Tenants
| Comparable Tenant | Rating | Cap Rate Range |
|---|---|---|
| CSL Plasma (CSL Behring) | A‑ / A3 | 5.25–6.25% |
| Fresenius | BBB‑ / Baa3 | 6.00–7.00% |
| DaVita Dialysis | BB / Ba3 | 6.50–8.00% |
Is BioLife Plasma investment grade?
Yes. BioLife Plasma Services is a wholly owned subsidiary of Takeda Pharmaceutical Company, which carries BBB‑ from S&P and Baa3 from Moody’s — minimum investment grade with stable outlooks. This makes BioLife one of the few plasma collection operators with a direct investment-grade parent guarantee on its NNN leases.
What cap rates are BioLife Plasma NNN properties trading at?
BioLife Plasma NNN properties trade at 5.75% to 6.75% as of Q1 2026. The BBB‑/Baa3 Takeda parent credit and the specialized plasma collection format support tighter pricing than unrated plasma operators. Acquisition prices typically range from $3,000,000 to $7,000,000.
The Only BioLife Plasma NNN Advisor Whose Fee Comes From the Deal, Not From You
In NNN buyer representation, the listing broker typically pays a cooperating commission to the buyer’s broker. On the majority of transactions, this means there is no separate fee to you as the buyer. Where a cooperating commission is not available, our compensation is agreed upon with you in advance so there are never surprises.
Find It — BioLife NNN centers sourced with donor traffic analysis, lease term, and Takeda entity guarantee confirmation before you commit.
Fund It — BBB‑/Baa3 pharma-backed healthcare credit. Life companies and CMBS lenders price this credit tier competitively.
Exit It — Selling a BioLife property? Investment-grade plasma collection is a differentiated story with consistent institutional buyer demand.
Get Your Free BioLife Plasma NNN Consultation →
In a 1031 exchange? Tell us your timeline — we move faster.
Related NNN Tenants
- Ascension
- Aspen Dental
- Athletico
- Concentra / Humana
- Corewell Health
- CSL Plasma
- DaVita Dialysis
- EyeCare Partners
- Fresenius
- Grifols
- Henry Ford Health
- HCA Healthcare
- Heartland Dental
- Mary Washington Healthcare
- McLaren Health Care
- Oak Street Health
- Piedmont Healthcare
- Sparrow Health
- Trinity Health
- U of M Health
- University of Pittsburgh Medical Center (UPMC)
- Acadia Healthcare
- AFC Urgent Care
- ATI Physical Therapy
- CityMD / Summit Health
- Encompass Health
- Fast Pace Urgent Care
- MedExpress Urgent Care
- MyEyeDr
- NextCare Urgent Care
- Octapharma Plasma
- Pacific Dental Services
- Select Physical Therapy
- Smile Brands
- VCA Animal Hospitals
- WellNow Urgent Care
- Banfield Pet Hospital
- Labcorp
- National Vision
- Quest Diagnostics
Own a BioLife Plasma Services Property? Capital Markets Strategies Beyond Selling
Maturing debt and considering refinancing? Our capital markets team maintains 150+ lender relationships underwriting NNN properties across investment-grade and non-investment-grade credit tiers. We structure rate-and-term refinancing, cash-out refis, and bridge-to-perm takeouts.
Evaluating a 1031 exchange or disposition? We represent both sides of BioLife Plasma Services NNN transactions — whether you are looking to exit at peak value, exchange into a higher-quality credit tenant, or reposition within the same sector.
Need a current valuation? We maintain live comps on BioLife Plasma Services NNN transactions and can produce a Broker Opinion of Value within 48 hours reflecting today’s cap rate market.
Own multiple BioLife Plasma Services properties? Considering an off-market sale?
Investment Grade represents owners on confidential disposition of BioLife Plasma Services portfolios and individual properties through off-market direct-to-principal distribution to specialty REITs, private equity funds, and family offices. BioLife Plasma Services buyer demand runs deep, and portfolio sales consistently produce stronger pricing than sequential individual sales because the institutional buyer pool is structured around portfolio acquisition.
For multi-property owners considering a portfolio disposition, see Selling Investment Grade NNN Off-Market: Tenant-by-Tenant Buyer Demand. For the full off-market framework covering individual property dispositions, sale-leasebacks, and 1031 coordination, see Off-Market CRE Sales: The Complete 2026 Guide.
The pre-listing conversation is at no cost and fully confidential. Email team@investmentgrade.com or see contact Investment Grade.
